Tejon Ranch Co.
NYSE:TRCConglomerates
-$0.06 today
- Market cap
- $465.26M
- Beta
- 0.59
- P/E (TTM)
- 296.5
- EPS (TTM)
- $0.06
Volume 0.26M
Average 0.09M
TRC Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Tejon Ranch Co.NYSE: TRC
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $695K fell 90.1% year over year, behind the -22.7% change in trailing-twelve-month financing cash flow. Sequentially, it fell 63.8% from the prior quarter.
Context
- Financing cash flow amounted to 53.3% of revenue in FY2025, up 8.4 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -90.1% toward the trailing-twelve-month pace of -22.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 26.43M USD
- Year-over-year change
- +40.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.43M | +40.6% |
| FY2024 | 2024-12-31 | 18.79M | +373.8% |
| FY2023 | 2023-12-31 | (6.87M) | -55.4% |
| FY2022 | 2022-12-31 | (4.42M) | +27.4% |
| FY2021 | 2021-12-31 | (6.09M) | — |
Financing Cash Flow vs competitors
How TRC compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -22.7% is the 6th highest of 9, against a peer median of +15.6%.
- Financing cash flow amounts to 39.5% of revenue for TRC, versus a peer median of 4.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | £119.15M GBP | — | +158.4% | — | |
| LTM Mar 2026 | $105.96M USD | -148.5% | -52.8% | 5.7% | |
| LTM Apr 2026 | $83M USD | +801.0% | — | 15.8% | |
| LTM Mar 2026 | $51.32M USD | -183.7% | -4.8% | 22.6% | |
| LTM Mar 2026 | $20.12M USD | -22.7% | — | 39.5% | |
| LTM Mar 2026 | $16.09M USD | +413.0% | +67.6% | 1.8% | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | $9.5M USD | +45.5% | +101.8% | 3.7% |
| LTM Mar 2026 | $5.16M USD | -14.3% | -58.2% | 27.8% | |
| LTM Mar 2026 | $4.18M USD | +304.4% | — | 0.5% | |
| LTM Apr 2026 | $1.09M USD | -99.6% | — | 0.1% | |
| Peer median (excluding TRC) | — | +15.6% | +31.4% | 4.7% | |
Competitors are the stored peer set for TRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 5.34M | 15.81M | 3.27M | 2.69M | 71K |
| Depreciation & Amortization | 4.59M | 4.63M | 4.81M | 4.89M | 6.01M |
| Deferred Income Tax | 1.13M | 2.87M | 1.12M | 784K | 782K |
| Stock-Based Compensation | 4.27M | 2.88M | 3.25M | 4.18M | 1.71M |
| Change in Working Capital | (96K) | 1.84M | (4.61M) | 3.21M | (2.8M) |
| Accounts Receivables | (814K) | 3.24M | (4.48M) | 261K | 2.27M |
| Inventory | 0 | 1.05M | 0 | 0 | 0 |
| Accounts Payables | 0 | (3.24M) | 0 | 0 | 0 |
| Other Working Capital | 718K | 786K | (132K) | 2.95M | (5.07M) |
| Other Non-Cash Items | (12.43M) | (19.49M) | 5.82M | (1.43M) | 356K |
| Operating Cash Flow | 2.82M | 8.53M | 13.66M | 14.31M | 6.13M |
| Capital Expenditures | (23.29M) | (23.59M) | (27.36M) | (66.11M) | (71.22M) |
| Acquisitions (Net) | (2.9M) | (800K) | (4.5M) | (346K) | (2.28M) |
| Purchases of Investments | (14.59M) | (63.88M) | (132.32M) | (74M) | (32.39M) |
| Sales of Investments | 6.25M | 41.14M | 137.8M | 92.61M | 31.64M |
| Other Investing Activities | 19.88M | 45.25M | 12.38M | 22.1M | 11.95M |
| Investing Cash Flow | (14.65M) | (1.89M) | (14M) | (25.75M) | (62.31M) |
| Debt Repayment | (4.3M) | (2.63M) | (2.42M) | 19M | 27M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (2.73M) | 0 | (206K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.79M) | 942K | (4.45M) | 0 | (569K) |
| Financing Cash Flow | (6.09M) | (4.42M) | (6.87M) | 18.79M | 26.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (17.92M) | 2.22M | (7.21M) | 7.36M | (29.74M) |
| Free Cash Flow | (20.48M) | (15.06M) | (13.71M) | (51.79M) | (65.09M) |
Tejon Ranch Co.
NYSE:TRC
Intrinsic Alpha fair value
Locked
Current Price
$17.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.